Calabrese Laura, Malvaso Dalma, Antonelli Flaminia, Mannino Maria, Peris Ketty, Chiricozzi Andrea
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Expert Opin Investig Drugs. 2023 Mar;32(3):229-243. doi: 10.1080/13543784.2023.2184684. Epub 2023 Mar 3.
The therapeutic armamentarium for the treatment of psoriasis, a chronic inflammatory skin disease, is now reasonably broad and structured, with several therapeutic agents that demonstrated a successful long-term control of this condition. However, there are still unfulfilled gaps resulting from the inherent limitations of existing therapies, which have paved the way for the identification of new therapeutic strategies or the improvement of the existing ones.
The aim of this review is to thoroughly explore new therapeutic strategies and novel drugs that are currently in the pipeline for the treatment of psoriasis, focusing primarily on agents that are currently in phase I/II of clinical development. Some of which retrace already existing therapeutic approaches, such as the IL23/Th17 pathway inhibition, while others unveil new and yet unexplored ones.
Since the therapeutic landscape of psoriasis is wide, it is not yet clear whether novel agents will fill the remaining gaps in the context of a broader and more diversified set of oral and biologic therapies. Nevertheless, with the development of precision medicine approaches, the development of innovative targeted drugs will still have a therapeutic rationale in psoriasis.
银屑病是一种慢性炎症性皮肤病，目前其治疗手段相当广泛且系统，有多种治疗药物已证明能成功实现对该病的长期控制。然而，现有疗法的固有局限性仍导致一些未被满足的差距，这为新治疗策略的确定或现有策略的改进铺平了道路。
本综述的目的是全面探索目前正在研发用于治疗银屑病的新治疗策略和新型药物，主要聚焦于目前处于临床开发I/II期的药物。其中一些回归了现有的治疗方法，如抑制IL23/Th17通路，而其他一些则揭示了新的、尚未探索的方法。
由于银屑病的治疗领域广泛，在更广泛、更多样化的口服和生物治疗背景下，新型药物是否能填补剩余差距尚不清楚。尽管如此，随着精准医学方法的发展，创新靶向药物的研发在银屑病治疗中仍将具有治疗依据。
